Reported 6 months ago
Some developers of psychedelic medicine are moving away from therapy-focused approaches, sparking concerns about the lack of necessary support for patients. As trials involving drugs like psilocybin progress, discussions have arisen about administering them without comprehensive therapeutic assistance, raising questions about the safety and efficacy of these treatments. This shift in approach, highlighted by companies like Compass Pathways and MindMed, is redefining the role of therapy in psychedelic medicine, prompting debates about the impact on patients and the broader future of psychedelics in clinical settings.
Source: YAHOO